Evotek to Partner With Ozempic Maker Novo Nordisk on Stem Cell Therapy
Provided by
Dow Jones
By Helena Smolak
Evotek entered a tech partnership with Ozempic maker Novo Nordisk to develop stem cell-based therapies.
The German biotech said Thursday that the Danish drug company, which makes weight-loss drugs Ozempic and Wegovy, will fund Evotec's research and development efforts through an undisclosed upfront payment and potential further milestone and royalty payments.
Novo Nordisk might obtain exclusive rights to the results of the deal.
Write to Helena Smolak at helena.smolak@wsj.com
(END) Dow Jones Newswires
September 26, 2024 04:30 ET (08:30 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
Undervalued by 25% and Yielding 5%, This Stock Is a Buy
-
Can AI Predict Future Stock Returns?
-
The Best Energy Stocks to Buy Now
-
10 Undervalued Wide-Moat Stocks
-
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?
-
New 4-Star Stocks
-
Intel Fair Value Left Unchanged Despite Qualcomm Takeover Talk
United States